Device Diabetes

Pogo Automatic Blood Glucose Monitoring System

Payments companies reported to CMS as associated with Pogo Automatic Blood Glucose Monitoring System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$255Kassociated payments (2023-2025)
831clinicians with associated payments
1company reporting

By year

2023 $255K

Payments reported as associated with Pogo Automatic Blood Glucose Monitoring System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Endocrinology, Diabetes & Metabolism $125K
Internal Medicine $26K
Medical $11K
Physician Assistant $10K
Family $7,098
Gastroenterology (Internal Medicine) $5,342

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Pogo Automatic Blood Glucose Monitoring System

These are the largest totals companies reported as associated with Pogo Automatic Blood Glucose Monitoring System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Philip Rabito New York, NY $31,753.72
Vinay Kapoor Manhasset, NY Endocrinology, Diabetes & Metabolism $19,868.92
Perry Herson Williston Park, NY $16,404.13
Andrew Henry Tampa, FL Endocrinology, Diabetes & Metabolism $10,934.29
Isaac Sachmechi New Hyde Park, NY Endocrinology, Diabetes & Metabolism $10,829.51
Benito Lopez Edinburg, TX Medical $7,375.45
Marc Sandberg Flemington, NJ Endocrinology, Diabetes & Metabolism $7,370.72
Damaris Vega Houston, TX Endocrinology, Diabetes & Metabolism $5,740.35
Ripudaman Hundal Newark, DE Endocrinology, Diabetes & Metabolism $5,600.00
Raya Galibov New York, NY Physician Assistant $5,532.38

Prescribed Pogo Automatic Blood Glucose Monitoring System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.